Biological
13-valent pneumococcal vaccine clinical trials
Also written PCV13.
- studies test it
- 128
- open now
- 2
- in phase 3
- 60
- first study started
- 2004
Keep track of what changes. Save the 13-valent pneumococcal vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- PCV13
- 26
Combined with it in one product
Studies by the year they started
127 studies that test it; most in 2013 (16)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 6 |
| 2007 | 14 |
| 2008 | 7 |
| 2009 | 5 |
| 2010 | 8 |
| 2011 | 5 |
| 2012 | 9 |
| 2013 | 16 |
| 2014 | 8 |
| 2015 | 8 |
| 2016 | 5 |
| 2017 | 7 |
| 2018 | 12 |
| 2019 | 6 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 7
- Phase 2
- 19
- Phase 3
- 60
- Phase 4
- 41
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 72 · Other 56
Pfizer (35) · Wyeth is now a wholly owned subsidiary of Pfizer (21) · GlaxoSmithKline (6) · University of Oxford (5) · Korea University Guro Hospital (4) · Sanofi Pasteur, a Sanofi Company (3) · Assistance Publique - Hôpitaux de Paris (2) · Helsinki University Central Hospital (2)
Often tested with
Tested in the same studies.
23-valent pneumococcal capsular polysaccharide vaccine (9) · Pneumococcal Vaccines (7) · 10-valent pneumococcal conjugate vaccine (4) · Influenza Vaccines (3) · Diphtheria-Tetanus-acellular Pertussis Vaccines (3) · Meningococcal Vaccines (3) · PHiD-CV vaccine (3) · Pneumococcal 20-Valent Conjugate Vaccine (2)
Studies
Open first, then newest update. How each study uses 13-valent pneumococcal vaccine is read from its arms, and is right about nine times in ten.
Testing it · 128
- Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a LymphomaRecruitingPhase 4Poitiers University HospitalNCT04460235Written as Prevenar 13 + Pneumovax 23
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in InfantsRecruitingPhase 2GlaxoSmithKlineNCT07286370Written as Prevenar 13
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT05412030Written as Prevnar 13
- Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in IndiaCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00452790Written as 13-valent Pneumococcal Conjugate Vaccine
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 YearsCompletedPhase 1Reinovax Biologics Co., LTDNCT06675032Written as 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Impact of HIV-1 and Aging on Mucosal Vaccine ResponsesActive, not recruitingEarly Phase 1VA Eastern Colorado Health Care SystemNCT03729778Written as Prevnar-13
- Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 YearsCompletedPhase 3PfizerNCT00761631Written as 13 valent pneumococcal conjugate vaccine
- Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.CompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT03873727Written as Prevenar13 (PCV13) and Pneumovax (PPS23)
- A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthCompletedPhase 1/2Janssen Research & Development, LLCNCT03819049Written as Prevnar 13
- A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In ChinaCompletedPhase 3PfizerNCT01692886Written as 13-valent Pnumococcal Conjugate vaccine
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese AdultsCompletedPhase 1PfizerNCT07019909Written as 13vPnC
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive, not recruitingPhase 1/2Sanofi Pasteur, a Sanofi CompanyNCT06647407Written as Pneumococcal 13-valent conjugate vaccine
- Genomics and Epigenomics of the Elderly Response to Pneumococcal VaccinesCompletedPhase 4The Jackson LaboratoryNCT03104075Written as Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein
- Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)Active, not recruitingNot applicableUniversity of California, Los AngelesNCT01527591Written as Pneumococcal Conjugate Vaccine 13 (PCV13)
- Influenza Vaccination for Flu Prevention in Patients With Plasma Cell DisordersCompletedPhase 4Emory UniversityNCT04080531Written as Pneumococcal 13-valent Conjugate Vaccine
- PCV13 + Hepatitis a Vaccine for AdultsCompletedPhase 4Helsinki University Central HospitalNCT01926860Written as Prevenar13
- Fever After Simultaneous Versus Sequential Vaccination in Young ChildrenCompletedPhase 4Duke UniversityNCT03165981Written as PCV13
- The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan InfantsCompletedPhase 4London School of Hygiene and Tropical MedicineNCT03489018Written as PCV13
- A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young ChildrenCompletedPhase 3PfizerNCT03574389Written as 13vPnC
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03691610Written as Pneumococcal 13-valent Conjugate Vaccine
See all 128 studies that test 13-valent pneumococcal vaccine →
Given in every arm · 54 — 13-valent pneumococcal vaccine is usual care beside what is tested
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingPhase 1/2Mayo ClinicNCT03942328Written as Pneumococcal 13-valent Conjugate Vaccine
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingPhase 4National Heart, Lung, and Blood Institute (NHLBI)NCT05170399Written as PREVNAR 13
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06740630Written as PCV (pneumococcal conjugate vaccine) 13
- A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06693895Written as PCV (pneumococcal conjugate vaccine) 13
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06806137Written as PCV (pneumococcal conjugate vaccine) 13
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06855160Written as PCV (pneumococcal conjugate vaccine) 13
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT03621670Written as Prevnar13
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 MonthsCompletedPhase 2Reinovax Biologics Co., LTDNCT07333352Written as 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)
- Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedPhase 1/2Mayo ClinicNCT03035331Written as Pneumococcal 13-valent Conjugate Vaccine
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedPhase 2Jennifer WoyachNCT02518555Written as Pneumococcal 13-valent Conjugate Vaccine
- Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate VaccineCompletedPhase 1/2Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06703203Written as 13-Valent pneumococcal conjugate vaccine
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT05794230Written as Pneumoccocal Vaccine
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab TherapyCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT03069703Written as PCV13
- Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete RemissionTerminatedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03376477Written as Prevnar13
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT05084508Written as 13-valent pneumococcal conjugate vaccine
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03537508Written as Pneumococcal 13-valent conjugate vaccine
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and ToddlersCompletedPhase 4GlaxoSmithKlineNCT04535037Written as Pneumococcal 13-valent conjugate vaccine
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03673462Written as Pneumococcal 13-valent Conjugate Vaccine
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United KingdomCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03632720Written as Pneumococcal 13-valent polysaccharide conjugate vaccine
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and MexicoCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03630705Written as Pneumococcal 13-valent Conjugate Vaccine
Showing 20 of 54.
As the comparator · 67 — what is tested is compared with 13-valent pneumococcal vaccine
- A Study to Evaluate 20vPnC in Healthy Chinese InfantsRecruitingPhase 3PfizerNCT07754539Written as 13vPnC
- Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)RecruitingPhase 1/2CanSino Biologics Inc.NCT07600983Written as PCV13 vaccine
- Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)Not yet recruitingPhase 3Sinovac Life Sciences Co., Ltd.NCT07593924Written as Prevenar 13™
- A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60Not yet recruitingPhase 1Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06970756Written as 13-valent Pneumococcal Conjugate Vaccine
- Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy VolunteersNot yet recruitingPhase 3Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT04357522Written as 13-Valent Pneumococcal Conjugate Vaccine
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and InfantActive, not recruitingPhase 1PfizerNCT07023081Written as 13vPnC
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Active, not recruitingPhase 3CanSino Biologics Inc.NCT07017777Written as Prevnar 13
- Clinical Trial of PCV24 in Children Aged 2-17 YearsCompletedPhase 1Sinovac Life Sciences Co., Ltd.NCT06550830Written as Prevenar13®
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedPhase 1Sinovac Research and Development Co., Ltd.NCT06183216Written as PREVNAR 13
- A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and TaiwanCompletedPhase 3PfizerNCT05512819Written as 13-valent pneumococcal conjugate vaccine
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT04398706Written as Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)CompletedPhase 1Merck Sharp & Dohme LLCNCT03848065Written as Pneumococcal 13-valent Conjugate Vaccine (PCV13)
- Extension Safety and Immunogenicity Study of GPNV-001CompletedPhase 1/2GPN VaccinesNCT05982314Written as Prevenar-13
- Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)CompletedPhase 1Sanofi Pasteur, a Sanofi CompanyNCT06698198Written as Prevnar 13®
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and TaiwanCompletedPhase 3PfizerNCT04875533Written as 13vPnC
- Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in InfantsActive, not recruitingPhase 3Fosun Adgenvax Biopharmaceutical Co.,Ltd.NCT05759520Written as Prevenar 13
- Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13CompletedPhase 3PfizerNCT05408429Written as 13-valent pneumococcal conjugate vaccine
- Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.CompletedPhase 1GPN VaccinesNCT05667740Written as Prevenar-13
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of AgeCompletedPhase 1PfizerNCT05489328Written as 13vPnC
- Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)CompletedPhase 3CanSino Biologics Inc.NCT04841369Written as 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Showing 20 of 67.